Literature DB >> 30231442

Defining a Central Monitoring Capability: Sharing the Experience of TransCelerate BioPharma's Approach, Part 1.

Brett Wilson1, Tom Provencher2, Jacqueline Gough3, Stephanie Clark4, Ramil Abdrachitov5, Karolien de Roeck6, Sarah Jane Constantine7, David Knepper8, Andy Lawton9.   

Abstract

Central monitoring, on-site monitoring, and off-site monitoring provide an integrated approach to clinical trial quality management. TransCelerate distinguishes central monitoring from other types of central data review activities and puts it in the context of an overall monitoring strategy. Any organization seeking to implement central monitoring will need people with the right skills, technology options that support a holistic review of study-related information, and adaptable processes. There are different approaches actively being used to implement central monitoring. This article provides a description of how companies are deploying central monitoring, as well as samples of the workflows that illustrate how some have implemented it. The desired outcomes include earlier, more predictive detection of quality issues. This paper describes the initial implementation steps designed to learn what organizational capabilities are necessary.

Entities:  

Keywords:  TransCelerate BioPharma; capabilities; central monitoring; implementation; risk-based monitoring

Year:  2014        PMID: 30231442     DOI: 10.1177/2168479014546335

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  Monitoring performance of sites within multicentre randomised trials: a systematic review of performance metrics.

Authors:  Kate F Walker; Julie Turzanski; Diane Whitham; Alan Montgomery; Lelia Duley
Journal:  Trials       Date:  2018-10-16       Impact factor: 2.279

2.  Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: Further analyses of findings from the prospective TEMPER triggered monitoring study.

Authors:  William J Cragg; Caroline Hurley; Victoria Yorke-Edwards; Sally P Stenning
Journal:  Clin Trials       Date:  2020-11-24       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.